The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients
Completed · Not applicable
Conditions studied: HIV Infections
In brief
The purpose of this study is to evaluate the effect of immediate versus deferred indinavir (IDV) in addition to background therapy on disease progression or death in patients with CD4+ cell counts between 200 and 500 cells/mm3 and plasma HIV RNA levels \>= 10,000 copies/ml. This study aims to examine two management strategies, immediate versus deferred IDV therapy, for their clinical effects in the context of background antiretroviral (AR) therapy, given according to current clinical practice. There is an urgent need to identify the optimal use of IDV in patient management, since clinical endpoint studies have not been completed in the United States. Since there is little information about the long term durability of clinical effects, and even less information about the timing of the initiation of protease inhibitor therapy, exploring the disease progression and survival impact of immediate versus delayed use of IDV will yield important information to guide clinical decision making for this group of patients.
Key facts
- Study ID
- NCT00000861
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 1900
- Expected to finish
- 1997-03-01
- Last updated by the study team
- 2021-10-28
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Concurrent Medication:
- Allowed:
- Topical and/or antifungal agents, except ketoconazole.
- Treatment, maintenance, or chemoprophylaxis with approved agents for OIs will be given as clinically indicated.
- Clinically indicated antibiotics, unless excluded.
- Systemic corticosteroid use for <21 days for acute problems is permitted as clinically indicated. However, chronic systemic corticosteroid use should be avoided.
- Recombinant erythropoietin (rEPO) and granulocyte-colony stimulating factor (G-CSF, filgrastim).
- Didanosine (ddI).
- Regularly prescribed medications, such as antipyretics, antidepressants, oral contraceptives, megestrol acetate, testosterone, or any other medication.
- Patients must have:
- A working diagnosis of HIV infection.
- A CD4+ count between 200 and 500 cells/mm3.
- Signed, informed parental consent if patient is less than 18.
- NOTE:
- The DAIDS Clinical Science Research Committee (CSRC) has deemed this protocol appropriate for prisoner enrollment.
You may not qualify if…
- Co-existing Condition:
- Patients with any of the following conditions or symptoms are excluded:
- Febrile illness with temperature > 38.5 degrees C (101.3 degrees F) within 3 days prior to study entry.
- Concurrent Medication:
- Excluded:
- Non-nucleoside reverse transcriptase inhibitors.
- Protease inhibitors except IDV.
- Rifabutin and rifampin.
- Ketoconazole.
- Terfenadine, astemizole, cisapride, triazolam and midazolam.
- Patients with any of the following prior conditions are excluded:
- History of prior saquinavir (SQV) therapy for more than 14 days.
- History of any prior protease inhibitor therapy other than SQV.
- History of serious opportunistic infection.
Where it is running
- Community Consortium of San Francisco — San Francisco, California, United States
- Denver CPCRA / Denver Public Hlth — Denver, Colorado, United States
- Veterans Administration Med Ctr / Regional AIDS Program — Washington D.C., District of Columbia, United States
- AIDS Research Consortium of Atlanta — Atlanta, Georgia, United States
- AIDS Research Alliance - Chicago — Chicago, Illinois, United States
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med — New Orleans, Louisiana, United States
- Comprehensive AIDS Alliance of Detroit — Detroit, Michigan, United States
- Henry Ford Hosp — Detroit, Michigan, United States
- Southern New Jersey AIDS Cln Trials / Dept of Med — Camden, New Jersey, United States
- North Jersey Community Research Initiative — Newark, New Jersey, United States
- Harlem AIDS Treatment Group / Harlem Hosp Ctr — New York, New York, United States
- Portland Veterans Adm Med Ctr / Rsch & Education Grp — Portland, Oregon, United States
- Philadelphia FIGHT — Philadelphia, Pennsylvania, United States
- Richmond AIDS Consortium — Richmond, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.